Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent Stem Cell Lysate to Induce Cytotoxic T Lymphocytes against HLA-A33-Matched Cancer Cells

• Published in: International journal of molecular sciences Vol. 23; no. 21; p. 12992
• Main Authors: Nakazawa, Tsutomu, Maeoka, Ryosuke, Morimoto, Takayuki, Matsuda, Ryosuke, Nakamura, Mitsutoshi, Nishimura, Fumihiko, Yamada, Shuichi, Nakagawa, Ichiro, Park, Young-Soo, Nakase, Hiroyuki, Tsujimura, Takahiro
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.11.2022; MDPI
• Subjects: Antigen (tumor-associated); Antigens; Antitumor activity; Autografts; Breast cancer; cancer immunotherapy; cancer vaccine; Cancer vaccines; Colorectal carcinoma; cytotoxic lymphocyte (CTL); Cytotoxicity; dendritic cell (DC); Dendritic cells; Enzyme-linked immunosorbent assay; Fibroblasts; Fluorescence; Gene expression; Glioblastoma; Glioblastoma cells; Histocompatibility antigen HLA; Immune system; Immunotherapy; induced pluripotent stem cell (iPSC); Leukocytes (mononuclear); Lymphocytes; Lymphocytes T; Melanoma; Mutation; Patients; Peptides; Peripheral blood mononuclear cells; Pluripotency; Stem cell transplantation; Stem cells; Tumors; Vaccines
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232112992

Irradiated murine induced-pluripotent stem cells (iPSCs) elicit the antitumor response in vivo. However, it is unclear whether human iPSCs would elicit antitumor effects. In the present study, we investigated the capability of human iPSC lysate (iPSL)-pulsed dendritic cells (DCs) (iPSL/DCs) to induce cancer-responsive cytotoxic T lymphocytes (CTLs) in vitro. iPSCs and DCs were induced from peripheral blood mononuclear cells isolated from a human leukocyte antigen (HLA)-A33 homozygous donor. The iPSL was pulsed with immature DCs, which were then stimulated to allow full maturation. The activated DCs were co-cultured with autologous CTLs and their responses to SW48 colorectal carcinoma cells (HLA-A32/A33), T47D breast cancer cells (HLA-A33/A33), and T98G glioblastoma cells (HLA-A02/A02) were tested with enzyme-linked immunospot (ELISPOT) assays. Comprehensive gene expression analysis revealed that the established iPSCs shared numerous tumor-associated antigens with the SW48 and T47D cells. Immunofluorescent analysis demonstrated that the fluorescent-labeled iPSL was captured by the immature DCs within 2 h. iPSL/DCs induced sufficient CTL numbers in 3 weeks for ELISPOT assays, which revealed that the induced CTLs responded to SW48 and T47D cells. Human iPSL/DCs induced cancer-responsive CTLs on HLA-A33-matched cancer cells in vitro and could be a promising universal cancer vaccine for treating and preventing cancer.